Basic Information
| LncRNA/CircRNA Name | lnc-FEZF2-9:2 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | parathyroid cancer |
| ICD-0-3 | NA |
| Methods | qPCR, Microarray |
| Sample | PC and PA tissue |
| Expression Pattern | down-regulated |
| Function Description | Four lncRNAs (LINC00959,lnc-FLT3-2:2, lnc-FEZF2-9:2, and lnc-RP11-1035H13.3.1-2:1) identified were significantly dysregulated in further RT-PCR validation. The global "lncRNA score" calculated from the lncRNAs above also differentiated parathyroid carcinomas from adenomas. |
| Pubmed ID | 30972448 |
| Year | 2019 |
| Title | Genome-wide analysis of differentially expressed lncRNA in sporadic parathyroid tumors. |
External Links
| Links for lnc-FEZF2-9:2 | GenBank HGNC NONCODE |
| Links for parathyroid cancer | OMIM COSMIC |